Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.0436 | 0.2429 | 0.3606 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0823 | 1 | 0.5 |
Schistosoma mansoni | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0656 | 0.6735 | 1 |
Mycobacterium leprae | PROBABLE THYMIDYLATE SYNTHASE THYA (TS) (TSASE) | 0.0656 | 0.6735 | 1 |
Echinococcus multilocularis | thymidylate synthase | 0.0656 | 0.6735 | 1 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0823 | 1 | 0.5 |
Brugia malayi | dihydrofolate reductase family protein | 0.0436 | 0.2429 | 0.3606 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.0823 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0312 | 0 | 0.5 |
Onchocerca volvulus | 0.0656 | 0.6735 | 0.5 | |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.0823 | 1 | 0.5 |
Brugia malayi | Dihydrofolate reductase | 0.0436 | 0.2429 | 0.3606 |
Brugia malayi | thymidylate synthase | 0.0656 | 0.6735 | 1 |
Loa Loa (eye worm) | thymidylate synthase | 0.0656 | 0.6735 | 1 |
Mycobacterium tuberculosis | Probable thymidylate synthase ThyA (ts) (TSASE) | 0.0656 | 0.6735 | 1 |
Mycobacterium ulcerans | thymidylate synthase | 0.0656 | 0.6735 | 1 |
Chlamydia trachomatis | dihydrofolate reductase | 0.0436 | 0.2429 | 0.5 |
Echinococcus granulosus | thymidylate synthase | 0.0656 | 0.6735 | 1 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.0823 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 51 uM | Antimalarial activity against Plasmodium falciparum 3D7 infected in O positive erythrocytes assessed as parasite lactate dehydrogenase activity after 72 hrs | ChEMBL. | 23659857 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.